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Brucella spp. are Gram-negative bacteria that behave as facultative intracellular parasites of a variety of mammals.
This genus includes smooth (S) and rough (R) species that carry S and R lipopolysaccharides (LPS), respectively.
S-LPS is a virulence factor, and mutants affected in the S-LPS O-polysaccharide (R mutants), core oligosaccharide
or both show attenuation. However, B. ovis is naturally R and is virulent in sheep. We studied the role of B. ovis
LPS in virulence by mutating the orthologues of wadA, wadB and wadC, three genes known to encode LPS core
glycosyltransferases in S brucellae. When mapped with antibodies to outer membrane proteins (Omps) and R-LPS,
wadB and wadC mutants displayed defects in LPS structure and outer membrane topology but inactivation of wadA
had little or no effect. Consistent with these observations, the wadB and wadC but not the wadA mutants were
attenuated in mice. When tested as vaccines, the wadB and wadC mutants protected mice against B. ovis
challenge. The results demonstrate that the LPS core is a structure essential for survival in vivo not only of S
brucellae but also of a naturally R Brucella pathogenic species, and they confirm our previous hypothesis that
the Brucella LPS core is a target for vaccine development. Since vaccine B. melitensis Rev 1 is S and thus interferes
in serological testing for S brucellae, wadB mutant represents a candidate vaccine to be evaluated against B. ovis
infection of sheep suitable for areas free of B. melitensis.Introduction
Brucellosis is a worldwide extended infectious disease
caused by the Gram-negative bacteria of the genus
Brucella. This genus includes several species among
which B. abortus preferentially infects cattle, B. suis
swine and wild-life and B. melitensis goats and sheep.
These three species are zoonotic and cause a grave and
debilitating disease in humans. Sheep can also be in-
fected by B. ovis, a non-zoonotic species. B. ovis bru-
cellosis is characterized by a decreased fertility in
rams, occasional abortions and a rise in perinatal mor-
tality [1,2]. These four Brucella species differ not only
in host range and pathogenicity but also in surface
characteristics. Whereas B. abortus, B. melitensis and* Correspondence: ilgoni@unav.es
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article, unless otherwise stated.B. suis carry a smooth (S) type lipopolysaccharide (LPS) in
the outer membrane, B. ovis LPS lacks the O-polysaccharide
typical of S-LPS and thus resembles in this feature the rough
(R) LPS mutants of S brucellae [3].
S-LPS is a major virulence factor of S Brucella species
[4]. In this molecule, the O-polysaccharide is linked to a
core oligosaccharide, which in turn is linked to the lipid
A. It has been known for decades that the O-polysaccharide
is essential in the virulence of B. abortus, B. melitensis and
B. suis, and that the lipid A is poorly recognized by innate
immunity [4]. In addition, the core oligosaccharide section
has been shown recently to hamper recognition by innate
immunity systems, including complement, bactericidal pep-
tides and the TLR4-MD2 complex [5]. It has been postu-
lated that the Brucella S-LPS core carries a lateral branch
that hinders access of innate immunity effector proteins andentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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and the existence of a branched structure has been con-
firmed by structural analysis (Figure 1) [8]. These findings
have opened the way for an analysis of the role of the LPS of
R Brucella species in virulence. Moreover, as delayed recog-
nition by innate immunity plays a major role in Brucella
virulence, core mutants represent candidates for the devel-
opment of vaccines triggering an early and thus protective
immunoresponse [6].
Sheep brucellosis caused by either B. melitensis or
B. ovis can be controlled by vaccination with the at-
tenuated strain B. melitensis Rev 1 and, in fact, this is
the only effective way to control sheep brucellosis in
areas with a high or moderate prevalence of the dis-
ease [9]. However, Rev 1 has several drawbacks: it causes
an antibody response interfering with the serological diag-
nosis of B. melitensis, is virulent in humans and resistant
to streptomycin, an antibiotic of choice for brucellosis
treatment [9]. Therefore, Rev 1 is forbidden in countries
where B. melitensis has been eradicated [9], which leads to
the increase of B. ovis infections in sheep. Thus, research
on B. ovis-specific vaccines is an area of intense research
[10-12]. Acellular vaccines can be an alternative, and at-
tempts have been carried out with whole cell and subcel-
lular extracts [13], recombinant proteins [14] or DNA
vaccines [15]. However, these strategies usually require
boosters and adjuvants or immune modulators to reach
an adequate Th1 response [10,16], with the ensuing in-
crease in costs and difficulties of implementation in exten-
sively bred sheep.
The purpose of the research reported here was twofold:
to study the involvement of LPS in B. ovis virulence and to
develop B. ovis-specific vaccine candidates that could over-
come the above-summarized drawbacks. To this end, we
built on previous genetic analyses that have shown that at
least three glycosyltransferases (wadA, wadB and wadC)
are necessary for the complete assembly of the core oligo-
saccharide of B. abortus and B. melitensis [5,7,17,18].GlcN
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Figure 1 Proposed structure of the Brucella core LPS as described by
oligosaccharide chain composed of four residues of glucosamine (GlcN), pl
Kdo II linked to another glucose from which the O-polysaccharide stems. QMaterials and methods
Bacterial strains and growth conditions
The bacterial strains and plasmids used in this work are
listed in Table 1. The parental strain B. ovis PA is a viru-
lent strain isolated from a naturally infected ram that
has been extensively used as a challenge for the evalu-
ation of B. ovis vaccines in rams and mice. B. ovis strains
were cultured on tryptic soy agar (TSA, Pronadisa,
Madrid, Spain) or in tryptic soy broth (TSB, Biomerieux,
Madrid, Spain) supplemented with 0.5% yeast extract
(YE, Merck, Madrid, Spain) or on Blood Agar Base No.
2 (BAB; Pronadisa), all supplemented with 5% porcine or
calf serum (TSA-YE-S, TSB-YE-S or BAB-S, respect-
ively). Incubations were performed at 37 °C in a 10%
CO2 atmosphere, and liquid cultures were shaken at low
intensity. E. coli was grown in Luria-Bertani broth (LB:
Becton Dickinson, Madrid, Spain). Nalidixic acid (Nal;
25 μg/mL), Kanamycin (Km; 50 μg/mL), Gentamicin
(Gm; 15 μg/mL) or sucrose (5% w/v) (all from Sigma-
Aldrich Ltd., Haverhill, United Kingdom) were used
when required.
DNA manipulations and sequence analyses
Plasmid and genomic DNA were isolated with Qiaprep
Miniprep (Qiagen GmbH, Hilden, Germany) and Ultra-
clean Microbial DNA Isolation Kit (MoBio Laborator-
ies, Carlsbad, CA, USA), respectively. When needed,
DNA was also purified from agarose gels using a Qiack
Gel extraction kit (Qiagen). DNA sequencing was per-
formed by the dideoxy method at the Sequencing Unit
of Centro de Investigación Médica Aplicada (CIMA,
Universidad de Navarra, Spain), and primers were syn-
thesized by Sigma-Aldrich Ltd. Searches for DNA and
protein homologies were carried out using the Kyoto
Encyclopedia of Genes and Genomes [21], EMBL-
European Bioinformatics Institute server [22] and
National Center for Biotechnology Information (NCBI)
database [23].GlcN
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lc ManManQuin
O-POLYSACCHARIDE
Per
. . .
Kubler-Kielb [8]. The core oligosaccharide is composed of a side
us glucose (Glc) and mannose (Man), the latter linked to Kdo I, with
uin: quinovosamine; Per: perosamine.
Table 1 Bacterial strains and plasmids used in this work
Bacterial strains/Plasmids Characteristic Source/Reference
Brucella ovis
PA virulent strain, natural NalR CITA collection
BoΔwadA PA in frame deletion mutant in wadA Δ58-679 This work
BoΔwadB PA in frame deletion mutant in wadB Δ49-195 This work
BoΔwadC PA in frame deletion mutant in wadC Δ17-306 This work
BoPA-Gm challenge strain, PA GmR UN collection
Brucella melitensis
Rev 1 reference vaccine CITA collection
E. coli
S17-1 λpir mating strain with plasmid RP4 inserted into the chromosome Simon et al. [19]
TOP10 F’ F− lacIq Tn 10 (TetR) mcrA Δ(mrr-hsdRMS-mcrBC) 80lacZ ΔM15 ΔlacX74
recA1alaD139 endA1 nupG
Invitrogen
Plasmids
pCR2.1 cloning vector Invitrogen
pJQK derivated of pJQ200KS+; KmR, GmS Scupham and Triplett [20]
pYRI-12 913-bp of B. abortus parental chromosomal DNA containing the wadA deletion allele,
generated by PCR and cloned into pCR2.1
This work
pYRI-13 BamHI-XbaI fragment from pYRI-12 cloned into the corresponding sites of pJQK This work
pYRI-1 570-bp of B. abortus parental chromosomal DNA containing the wadB deletion allele,
generated by PCR and cloned into pCR2.1
Gil-Ramírez et al. [7]
pYRI-2 BamHI-XbaI fragment from pYRI-1 cloned into the corresponding sites of pJQK Gil-Ramírez et al. [7]
pYRI-14 934-bp of B. ovis parental chromosomal DNA containing the wadC deletion allele,
generated by PCR and cloned into pCR2.1
This work
pYRI-15 BamHI-XbaI fragment from pYRI-14 cloned into the corresponding sites of pJQK This work
CITA, Centro de investigación y tecnología agroalimentaria; UN, Universidad de Navarra.
Table 2 Primers used in the study
Gene Sequence (5’– > 3’)
wadA F1 CCC ACG CTG CTT AGT ACG TT
R2 CAT CAA AAC GTG CAT CGT CAA
F3 ATT GAC GAT GCA CGT TTT GAT GCA TTC
GGC TTT GCC TTT TAT
R4 GAG TTT ATC GCC CAA TTT GC
R5 TCT TCC AGA ATG AGG CCG TA
wadB F1 GCA TGA TTA CCC CGC TGAT
R2 CGC AAT CTC GTC TTT GTT GAG
F3 CTC AAC AAA GAC GAG ATT GCG GGT
GGC GTG AAG GAA ATCT
R4 TGA TAG CCG AGC CTC TTC AG
R5 ATG CAC CCA TGA AGT TTT CC
wadC F1 CTG GCG TCA GCA ATC AGA G
R2 GTG CAA CGA CCT CAA CTT CC
F3 GGA AGT TGA GGT CGT TGC ACA CGC
CAT CGA ACC TTA TCT G
R4 CGG CTA TCG TGC GAT TCT
R5 GCA ATG GAA TGA GCT GAA CA
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In-frame deletion mutants on selected genes were con-
structed by PCR overlap using genomic DNA of B. ovis
PA as a DNA template. Primers were designed based on
the sequence of B. ovis ATCC 25840 (also known as 63/
290 or NCTC10512; accession numbers NC_009505.1
and NC_009504.1). They are listed in Table 2. For inacti-
vation of wadC (BOV_1453), we first generated two
PCR fragments: the 5′end of the gene BOV_1453 was
amplified with primers wadC-F1 and wadC-R2 obtaining
a 473-bp fragment including codons 1 to 16 of the wadC
ORF, as well as 424-bp upstream of the wadC start
codon; whereas the 3′end was amplified with primers
wadC-F3 and wadC-R4 obtaining a 481-bp fragment in-
cluding codons 307 to 355 of the wadC ORF and 315-bp
downstream of the wadC stop codon. Both fragments
were ligated by overlapping PCR using primers wadC-F1
and wadC-R4. The resulting fragments containing the
wadC deletion allele, was cloned into pCR2.1 vector to
generate plasmids pYRI-14 (Table 1), sequenced to en-
sure the maintenance of the reading frame, and subse-
quently subcloned into the BamHI and the XbaI sites of
the suicide plasmid pJQK. The resulting mutator plas-
mid (pYRI-15, Table 1) was introduced in B. ovis PA by
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ation event (integration of the suicide vector in the
chromosome) was selected by Nal and Km resistance,
and the second (excision of the mutator plasmid leading
to the deletion mutant strain by allelic exchange) by Nal
and sucrose resistance and Km sensitivity. The resulting
colonies were screened by PCR with primers wadC-F1
and wadC-R4, which amplify a fragment of 934-bp in
the mutant strain and a fragment of 1804-bp in the paren-
tal strain. An additional PCR was carried out to exclude
the presence of the complete gene. The amplification was
done with primers wadC-F1 and wadC-R5, which include
a fragment from the deleted region of the gene. While
strains carrying the complete gene amplified a 533-bp
fragment, the mutant strain was unable to amplify the
fragment (see Additional file 1). The deletion was con-
firmed by sequencing. As a result of the mutation 82% of
the wadC ORF was lost, and the mutant strain was called
BoΔwadC (Table 1).
The ΔwadA mutant (BOV_0614) was obtained in a
similar way. Briefly, primers wadA-F1 and wadA-R2
were used to amplify a 453-bp fragment including codon
1 to 57 of the 5′end of wadA (BOV_0614), as well as
284-bp upstream of the wadA start codon; and primers
wadA-F3 and wadA-R4 were used to amplify a 460-bp
fragment including codons 680 to 704 of the wadA ORF
and 386-bp downstream of the wadA stop codon. Both
fragments were ligated by overlapping PCR using
primers wadA-F1 and wadA-R4, the resulting fragment
was cloned into pCR2.1, sequenced and subcloned into
pJQK. The resulting mutator plasmid (pYRI-13, Table 1)
was introduced in B. ovis PA by electroporation with a
micropulser (Bio-Rad, Hercules, CA, USA) as described
before [24]. The first recombination event was selected
by Km resistance, and the second by sucrose resistance
and Km sensitivity. The resulting colonies were screened
by PCR with primers wadA-F1 and wadA-R4, which
amplify a fragment of 913-bp in the mutant strain and a
fragment of 2782-bp in the parental strain. An additional
PCR was carried out to exclude the presence of the
complete gene. The amplification was done with primers
wadA-F1 and wadA-R5, which include a fragment from
the deleted region of the gene. While strains carrying
the complete gene amplified a 565-bp fragment, no
amplification was obtained with the mutant strain (see
Additional file 1). The deletion was confirmed by sequen-
cing. As a result of the mutation 82% of the wadA ORF
was lost and the mutant strain was called BoΔwadA
(Table 1).
Taking into account that the wadB sequence of B. abortus
2308 and B. ovis PA are almost identical (99.86% homology
with only one base pair change in the deleted section of the
gene), we used the mutator plasmid pYRI-2 (Table 1)
that was previously constructed to generate ΔwadB(BAB1_0351) mutants in B. abortus 2308 for the con-
struction of the B. ovis ΔwadB mutant [7]. The muta-
tor plasmid pYRI-2 was introduced in B. ovis PA by
conjugation. The resulting colonies were screened by
PCR with primers wadB-F1 and wadB-R4, which amp-
lify a fragment of 570-bp in the mutant strain and a
fragment of 1011-bp in the parental strain. An add-
itional PCR was carried out to exclude the presence of
the complete gene. The amplification was done with
primers wadB-F1 and wadB-R5, which include a frag-
ment from the deleted region of the gene. While strains
carrying the complete gene amplified a 471-bp fragment,
the mutant strain was unable to amplify the fragment
(Additional file 1). The deletion was confirmed by sequen-
cing. As a result of the mutation 60% of the wadB ORF
was lost, and the mutant strain was called BoΔwadB
(Table 1).
In all mutagenesis experiments, after the second re-
combination, two type of colonies Nal and sucrose re-
sistant and Km sensitive could be isolated: the deletion
mutant strain and the strain that had reverted to the
wild-type genotype (hereafter “sibling revertant strain”).
The latter was also selected as control for additional mu-
tations elsewhere in the chromosome that may have
been acquired during the manipulations described above,
and the genotypes of all the strains were confirmed by
PCR amplification and sequencing of the target locus in
the genome. Moreover, both mutant and sibling revertant
strains were characterized following standard Brucella
typing procedures [25], and purity checked by inhibition
of growth on BAB-S supplemented with Km.
LPS extraction and characterization
Extraction of whole-cell LPS by SDS-proteinase K proto-
col was performed as described by Dubray and Limet
[26] with modifications. Briefly, heat inactivated cells
were suspended in 0.0625 M Tris–HCl buffer (pH 6.8)
containing 2% SDS (wt/wt). Samples were heated at
100 °C for 10 min, and the lysates were tempered to 55 °C
and digested twice with proteinase K (10 mg/mL, one
hour at 55 °C). After that, samples were kept overnight at
20 °C and then stored at −20 °C. LPS were analysed in
Tris-Tricine-HCl-glycine poliacrilamyde gel electrophor-
esis (Tricine SDS-PAGE) as described by Lesse [27].
Briefly, a 16 × 20 cm two-phase gel (18% acrylamide-
bisacrylamide for the running gel and 4% for the stacking
gel) was prepared in 1 M Tris 0.1% SDS, pH 8.45. The gel
was placed between anode and cathode buffers (0.2 M
Tris–HCl pH 8.9 and 0.2 M Tris–HCl, 0.1 M Tricine,
0.1% SDS pH 8.45, respectively) and the electrophoresis
was carried out at constant voltage for one h at 30 V
followed by 20 h at 70 V. LPS was stained by the
periodate-alkaline silver method [28]. For Western blots,
LPS was electrotransferred onto nitrocellulose membranes,
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cubated with specific monoclonal antibodies (MAbs, see
below) overnight. After washing, bound immunoglobulins
were detected by chemiluminiscence (Thermo Fisher
Scientific Inc., Waltham, USA) with goat anti mouse
IgG (H + L) chain specific B. ovis conjugate secondary
antibodies (Merk4Biosciencies, Damstadt, Germany).
Surface topology mapping
Outer membrane proteins (Omp) and LPS exposure on
the cell surface was assessed by ELISA with the follow-
ing MAbs: A76/08C03/G03 for Omp16, A76/05C10/A08
for Omp19, A68/25G05/A05, A68/15B06/C08 and A63/
04D11/G01 for Omp2b, A59/05F01/C09 for Omp25,
A59/10F09/G10 for Omp31, and A68/24G12/A08, A68/
24D08/G09 and A68/10A06/B11 for R-LPS [29-32].
ELISA using whole bacteria as the antigen were per-
formed as described previously [32,33] with some modi-
fications. Briefly, lyophilized bacteria were resuspended
up to OD600 1 in phosphate-buffered saline pH 7.4 (PBS).
For coating, this suspension was distributed (100 μL/well)
in 96 flat bottom plates (Thermo Scientific) and incubated
overnight at room temperature. One-hundred microliters
of MAbs (hybridoma supernatant diluted 1:3 in 0.05%
Tween PBS) were incubated 37 °C for 1 h. Bound MAbs
were then detected with an affinity-purified goat anti-
mouse immunoglobulin G (H + L chains) – horseradish
peroxidase conjugate (Bio-Rad, Hercules, CA, USA) (di-
luted 1:6000 in 0.05% Tween PBS) incubated for 1 h at
room temperature. Between all the previous steps five
washes with 250 μL 0.05% Tween PBS were performed in
order to eliminate the excess of MAbs and conjugate.
Enzyme activity was revealed by the addition of TMB
ELISA peroxidase substrate (Interchim, Montlucon,
France) and stopped after 20 min at room temperature
with 1 M HCl based stop solution (Interchim). Plates
were read at 450 nm with a microplate reader (Thermo
Fisher Scientific Inc.).
Physico-chemical surface properties
Autoagglutination capacity was evaluated by measuring
the OD600 evolution of a bacterial suspension in TSB-
YE-S, over 48 h of static incubation at room temperature,
starting from initial readings of 0.8 (100% OD600) in TSB-
YE-S [24]. The results were represented as the mean ± SD
of the values obtained for three assays at each time
point, in three independent assays. The surface charge
density was measured as the electrophoretically effective
potential (Zeta potential) [18]. For this, bacteria were
inactivated with 0.5% phenol, washed and resuspended
in 0.1 M KCl, 10 mM HEPES 10 mM (pH 7.2) at an
OD600 of 0.1. Measurements were performed at 25 °C
in a Zetamaster instrument using the PCS 1.27 soft-
ware (Malvern Instruments Ltd., Malvern, UK) andthe settings of aqueous solutions (viscosity = 1.002 cP;
dielectric constant = 80.4), in plain buffer.
Susceptibility to nonimmune serum and polymyxin B
Sensitivity to the bactericidal action of nonimmune
serum was determined as follows: exponentially growing
bacteria were adjusted to 2 × 104 CFU/mL in PBS and
dispensed in microtiter plates (50 μL/well) containing
fresh normal calf serum or serum previously heated at
56 °C for 60 min to remove complement (150 μL/well).
After incubation for 3 h at 37 °C, 50 μL of each sample
was plated TSA-YE-S by triplicate, and the results are
expressed as the proportion between the organism cul-
tivable after exposure to normal nonimmune serum and
those cultivable after the exposure to serum in which
complement had been heat inactivated. Sensitivity to
polymyxin B (Sigma-Aldrich Ltd.) was determined as de-
scribed before [24].
Virulence and vaccine efficacy studies in mice
Female 8–10 week-old BALB/c mice (Charles River
International, France) were used. They were randomly
distributed and accommodated in the animal facilities of
Universidad Pública de Navarra (registration code ES/
31-2016-000002 CR-SU-US) for 1–2 weeks before start-
ing and during the assays, with water and food ad libitum.
The procedures performed with mice were designed
according to national (RD 53/2013) and European (EU
directive 2010/63) legislations regarding the use of ani-
mals in research. Mice inoculations were carried out
with 0.1 mL of bacterial suspensions previously adjusted
to an OD600 of 0.170 (around 1 × 10
9 CFU/mL) and then
diluted to the appropriate dose (see below) in sterile PBS
[34]. Exact inoculation doses were determined retrospect-
ively by plating tenfold dilutions prepared in PBS on
BAB-S or TSA-YE-S.
For virulence, BALB/c mice (n = 10) were inoculated
intraperitoneally (IP) with 5–7 × 105 CFU/mouse of the
corresponding B. ovis PA mutant strain, and viable
spleen counts were determined (n = 5) at 3 and 10 weeks
post-inoculation as previously detailed [34]. As a control,
additional groups of mice (n = 10) were inoculated simi-
larly with the virulent B. ovis PA reference or the sibling
reverting strains, to control for the potential for inciden-
tal attenuation during the manipulation required for
mutagenesis. The identity of the spleen isolates was
confirmed throughout the experiment by both PCR
and B. ovis phenotypic features [25]. Spleen infections
were expressed as mean ± SD (n = 5) of individual
log10 CFU/spleen at the times indicated [34].
Efficacy of the BoΔwadB and BoΔwadC mutants as
vaccines was evaluated in BALB/c mice (n = 10) vacci-
nated intraperitoneally with 1 × 108 CFU/mouse of the
corresponding B. ovis mutant strain, or subcutaneously
Figure 2 LPS characterization. Tricine SDS-PAGE (A) and Western-blot
(B) analysis of the LPS of B. ovis PA (1) and the LPS mutants BoΔwadA (2),
BoΔwadB (3) and BoΔwadC (4). Arrows point the components I, II and III
found by migration in the gel. The antibody used in the blot shown (B) is
anti R-LPS A68/10A06/B11. Western blot probed with A68/24G12/A08, and
A68/24D08/G09 gave similar results (data not shown).
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standard vaccinated control), or with 0.1 mL of PBS
(pH 6.8) as the unvaccinated control. Four weeks after
vaccination, all mice were challenged intraperitoneally
with 5 × 105 CFU/mouse of the virulent B. ovis PA-GmR
(Table 1), and the number of challenge bacteria in spleens
was determined 3 weeks afterwards [35]. Differentiation
between challenge and residual vaccine bacteria was per-
formed by duplicate plating on BAB-S and BAB-S supple-
mented with Gm. Results are expressed as the mean and
SD (n = 10) of the individual log10 CFU/spleen of B. ovis
PA-GmR challenge strain. Statistical comparisons of mean
log10 CFU/spleen were performed by a one-way ANOVA
followed by the Fisher’s Protected Least Significant Differ-
ences tests [34]. The virulence of the B. ovis PA-GmR chal-
lenge strain used in this work was proved in a previous
experiment in BALB/c mice (n = 5) by intraperitoneal in-
fection (5 × 105 CFU/mouse) and bacterial spleen count-
ing at 3 weeks later. This strain showed identical bacterial
counts in BAB-S and BAB-S supplemented with Gm, and
identical multiplication to that of B. ovis PA in mice (not
shown).
Results
Construction of B. ovis LPS mutants
Several ORF encoding putative glycosyltransferases have
been shown to be involved in the biosynthesis of the
core of B. abortus LPS: wadA (formerly named wa**,
BAB1_0639, [17,18]), wadB (BAB1_0351, [6,7]) and wadC
(BAB1_1522, [5,6]). We searched for orthologues of these
glycosyltransferases in the B. ovis strain ATCC25840 gen-
ome sequence and we identified three ORF: BOV_0614
for wadA, BOV_0337 for wadB and BOV_1453 for wadC,
with 99.4%, 99.9% and 100% DNA sequence identity, re-
spectively. Non-polar mutant and sibling revertant strains
were obtained for each target gene from B. ovis PA strain
as described in the Materials and methods section. PCR
amplification and sequencing of the target loci in the gen-
ome of the mutants confirmed inactivation of the respect-
ive genes (data not shown). All mutants behaved like the
parental strain in classical bacteriological typing for the
genus Brucella [25] and showed no differences in growth
patterns when compared to the parental strain B. ovis PA
(data not shown).
B. ovis wadB and wadC are required for the synthesis of a
complete LPS
For the analysis of possible LPS defects, we extracted
B. ovis LPS using a SDS-proteinase K protocol [26].
Tricine SDS-PAGE resolved the LPS of the parental
strain B. ovis PA into at least three major components
I, II and III (Figure 2A), and the same migration pat-
tern was obtained with the BoΔwadA mutant and the sib-
ling revertant strain (not shown). However, component Iwas absent from LPS of mutants BoΔwadB and BoΔ-
wadC, which also showed increased relative proportions
of component II, suggesting a deficiency in the LPS
oligosaccharide structure. The corresponding blots were
probed with anti-R-LPS MAbs A68/10A06/B11, A68/
24G12/A08, and A68/24D08/G09 (Figure 2B). The lack of
reactivity of these MAbs with the LPS of mutants BoΔ-
wadB and BoΔwadC confirmed the absence of part of the
oligosaccharide. In contrast, no defect could be detected
in the LPS of mutant BoΔwadA by this method.LPS gene mutants of B. ovis have altered key topological,
physicochemical and biological surface properties
Several differences were found between two B. ovis LPS
gene deletion mutants and the parental strain with re-
gard to their reactivity with MAbs specific for R-LPS
and Omps. When probed with anti-R-LPS antibodies,
differences in reactivity suggestive of changes in epitopic
structure and/or exposure were found: mutants BoΔwadB
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BoΔwadA had levels of reactivity similar to those of the
parental strain (Figure 3A). In addition, the binding of
anti-Omp MAbs to both BoΔwadB and BoΔwadC mu-
tants revealed significant differences compared to the par-
ental strain: while BoΔwadB reacted more strongly with
MAbs against the major Omps Omp25, Omp31 and also
the lipoproteins Omp16 and Omp19, BoΔwadC had de-
creased reactivity with all the anti-Omp MAbs (Figure 3B).
Similarly, the anti-Omp2b MAbs A68/25G05/A05 and
A68/15B06/C08 bound more strongly to BoΔwadB than
parental B. ovis PA, and very low levels of reactivity with
BoΔwadC; however, the anti-Omp2b MAb A63/04D11/
G01 displayed increased binding to BoΔwadC and a low
binding to BoΔwadB. These results suggest that the de-
fects in the LPS oligosaccharide of both mutants are dif-
ferent and affect the exposure and/or conformation of the
major Omps also in a different way. The MAb reactivity
of the major Omps in the BoΔwadA mutant was similar
to that of the parental strain in all the MAbs tested exceptFigure 3 Outer membrane epitopes in B. ovis PA and the LPS
mutants. Reactivity with MAbs anti R-LPS (A) and anti Omps (B) was
measured by ELISA.the antibody directed against Omp31 A59/10F09/G10
which showed an increased reactivity (Figure 3B).
Autoagglutination is a property characteristic of some
Brucella R mutants. Parental B. ovis PA, BoΔwadA and
all the sibling revertant strains showed autoagglutina-
tion, with a 90% reduction of the initial OD600 value in a
few hours. On the contrary, mutants BoΔwadB and
BoΔwadC remained in suspension for at least 48 h
(Figure 4). This effect correlated with an increase in
negative surface charge (Zeta potential, Figure 5). We
also studied whether the resistance to complement-
mediated killing in normal serum typical of brucellae was
affected by the mutations [36]. We found that, whereas the
parental strain B. ovis PA, BoΔwadA and the sibling revert-
ant strain were resistant to non-immune serum (survival
percentages of 93.0 ± 5.5, 92.0 ± 4.8, 101 ± 6.9, respect-
ively), BoΔwadB and BoΔwadC mutants were significantly
(p < 0.05) affected (survival percentages of 74.0 ± 3.9 and
68.0 ± 3.2, respectively). On the contrary, polymyxin B
resistance, another important envelope property of brucel-
lae, was not significantly affected (not shown).Both BoΔwadB and BoΔwadC mutants are attenuated and
protect against B. ovis PA infection in mice
The colonization and persistence of B. ovis LPS gene de-
letion mutants in the spleens of mice was evaluated at 3
and 10 weeks after intraperitoneal infection with 5–7 ×
105 CFU/mouse. While the infection produced by BoΔ-
wadA reached the levels of infection of B. ovis PA, mutants
BoΔwadB and BoΔwadC showed significant (p < 0.005) at-
tenuation (Table 3). In fact, the splenic concentrations
reached by the latter mutants at 3 weeks post-infectionFigure 4 Autoagglutination properties of B. ovis PA and the
LPS mutants. Results are the mean ± SD of three independent
experiments. Sibling revertant strains behaved as the parental strain
(data not shown).
Figure 5 Surface charge (Z potential) of B. ovis and the LPS
mutants. Results are the mean ± SD of ten independent
experiments. BoΔwadC-rev is the sibling revertant strain of the
BoΔwadC mutant, and the same results were obtained with
BoΔwadB-rev (not shown).
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tions are reached by virulent strains) were significantly
(p < 0.005) lower than that reached by the parental strain.
Thereafter, at 10 weeks post-infection, BoΔwadA persisted
at the levels of the parental strain while BoΔwadB and
BoΔwadC mutants showed significantly (p < 0.005)
reduced persistence, being practically cleared from the
spleens in most of the inoculated mice (Table 3). Such sig-
nificant attenuation was not attributable to the mutagen-
esis procedure, since both sibling revertant strains reached
and maintained levels of splenic infections similar to those
reached by the parental strain (Table 3).
The efficacy of BoΔwadB and BoΔwadC as vaccines
was studied in mice challenged with B. ovis PA. AsTable 3 Colonization of B. ovis PA and the LPS mutant
strains in mouse spleens
B. ovis strain log10 CFU in spleen
3 weeks post infection 10 weeks post infection
mean ± SD mean ± SD Cleared/Totals
B. ovis PA 6.56 ± 0.52 4.67 ± 0.86 0/5
BoΔwadA 6.78 ± 0.40 4.41 ± 2.01 0/5
BoΔwadB 2.31 ± 1.91a 0.80 ± 0.42a 5/5a
BoΔwadC 3.82 ± 0.72a 1.11 ± 0.77a 4/5a
BoΔwadB-revb 5.89 ± 0.77 4.90 ± 0.45 0/5
BoΔwadC-revb 6.49 ± 0.23 4.71 ± 1.68 0/5
Statistical comparison (n = 5) of mean log CFU/spleen or percentage of mice
found free from infection in spleens by totals, respectively: aP < 0.005 vs. B. ovis
PA; bSibling revertant mutants.shown in Table 4, these two mutants conferred signifi-
cant protection with respect to the unvaccinated con-
trols. However, the protection conferred by BoΔwadB
was the most effective one, improving significantly (p <
0.05) that conferred by others at standard conditions,
and even preventing the virulent infection in 7 out 10
mice (Table 4).Discussion
Several differences have been shown in the structure
of the LPS among the different species of the genus
Brucella [37-40]. Wild-type B. melitensis, B. abortus,
B. suis, B. neotomae, B. ceti, B. pinnipedialis and B. microti
produce a S-LPS where the O-polysaccharide is linked to
the core oligosaccharide. However, B. ovis and B. canis
lack this O-polysaccharide thus producing an R-LPS. The
genetic bases of this R phenotype have been partially de-
scribed [41]. In B. ovis, the genome shows a 15 Kb dele-
tion which includes genes wboA and wboB [41,42], both
involved in the synthesis of the O-polysaccharide, and sev-
eral point mutations generating nonfunctional proteins,
wbkF and wzt among others [43], involved in bactoprenol
priming (see also below) and export of the O-polysaccharide
to the periplasm, respectively.
The structures of the core and repeated O-polysaccharide
fragments of B. abortus biovar 4, B. melitensis biovar 3 and
B. suis biovar 4 obtained after acid hydrolysis of S-LPS have
been recently published [8]. The structure available for the
core oligosaccharide (Figure 1) shows the existence of a side
oligosaccharide chain composed of four residues of glucosa-
mine, plus glucose and mannose, the latter linked to Kdo I,
with Kdo II linked to another glucose from which the
O-polysaccharide stems. Although the precise struc-
ture of LPS of B. ovis remains to be determined, a pre-
vious immunochemical assay carried out with R-LPS
extracted from B. ovis REO198 found fragments that
were estimated to contain 2, 4, 6 and 7 sugars, includ-
ing glucose, mannose, glucosamine, Kdo and an unidenti-
fied sugar [44]. Up to now only three glycosyltransferases
have been shown to be involved in the synthesis of the
LPS core in B. abortus and B. melitensis (wadA, wadB andTable 4 Efficacy of B. ovis LPS mutants in BALB/c mice
against a virulent B. ovis infection
Vaccine (dose/route) Log10 CFU in spleen
(mean ± SD)
No. of non-infected/
total mice studied
BoΔwadB (108/IP) 1.08 ± 1.22a,c 7/10a,c
BoΔwadC (108/IP) 2.18 ± 1.59a 5/10b
B. melitensis Rev 1
(105/SC)
2.75 ± 1.26b 2/10
PBS (unvaccinated
control)
6.24 ± 0.48c 0/10
ap < 0.005 and , bp < 0.05 vs. unvaccinated control; cp < 0.05 vs. Rev 1 control.
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ORF. Although the homology of these glycosyltransferases
suggests that the composition of B. ovis core LPS is similar
to other Brucella species, antigenic and immunochemical
analyses of LPS extracts have showed differences [3,45].
In B. abortus and B. melitensis, the deletion of wadA
results in an R phenotype and an altered LPS core
[17,18]. In B. melitensis, the wadA mutant carries a de-
fective LPS core but also synthesizes a free cytoplasmic
O-polysaccharide, which strongly suggests that wadA
codes for a glycosyltransferase involved in the synthesis
of the core section linked to the O-polysaccharide [18].
Taking into account previous electrophoretic analysis of
the R-LPS, wadA is likely to encode the enzyme involved
in transferring the glucose linked to quinovosamine [18]
(Figure 1). In the case of B. ovis, the reactivity with
MAbs, the cell surface properties, the electrophoretic
analyses of the LPS and the virulence assays all showed
a similar behavior for mutant BoΔwadA and the parental
strain. Quinovosamine, absent in B. ovis REO 198 LPS
[45], is in all likelihood the sugar priming bactoprenol
for O-polysaccharide synthesis [18], and B. ovis carries
mutations in wbkF, involved in bactoprenol priming, so
LPS oligosaccharide lacks a terminal glucose in the
wadA mutants. Such a small defect would be consistent
with the fact that the B. ovis ΔwadA mutant was practic-
ally indistinguishable from the parental strain.
Although the LPS core of B. abortus and B. melitensis
mutants is altered, the O-polysaccharide remains in
place [5–7 and Conde R., Arce-Gorvel V., Iriarte M.,
Gorvel J.P. and Moriyón I., unpublished results]. This
evidence shows that glycosyltransferases WadB and
WadC are responsible for the synthesis of the glucosamine
rich oligosaccharide stemming from Kdo II (Figure 1). Spe-
cifically, it has been proposed that WadC could be impli-
cated in the transfer of the first mannose to the lateral
chain, while WadB would transfer other sugar [6,7]. In
B. abortus, both mutants induce a pro-inflammatory
response higher than that of wild-type bacteria and
are thus attenuated in dendritic cells and mice [5-7].
Moreover, they are more sensitive to the bactericidal
action of the nonimmune serum and cationic peptides
[5,7]. It has also been proved that the core defect enhances
recognition by the TLR4-MD2 receptor/co-receptor sys-
tem and, accordingly, a glucosamine-rich branch of the
LPS core of the B. abortus and B. melitensis acts as a shield
against recognition by several innate immune systems, thus
representing a virulence mechanism of these Brucella spp.
[5]. In B. ovis, the LPS of the mutants ΔwadB and ΔwadC
lacks a part of the core oligosaccharide (component I in
Figure 2) and the defects generate a marked increase in the
negative value of zeta potential that can be explained by
the loss of all or part of the positively charged glucosamine
residues (Figure 1). The attenuation observed for mutantsBoΔwadB and BoΔwadC show for the first time that
the LPS of a naturally R Brucella pathogenic species
(i.e. B. ovis) is essential for survival in the mouse
model. Even though the exact mechanism remains to
be elucidated, the proposed core defect is likely to fa-
cilitate the recognition of B. ovis LPS by innate im-
munity. Indeed, this hypothesis is supported by the
above-summarized results obtained with the homologous
B. abortus and B. melitensis mutants and with the fact
that, rather than the O-polysaccharide, it is the lipid A-core
overall structure that is recognized by multiple innate
immunity systems [5-7,17,18]. Nevertheless, other effects
cannot be disregarded because the mutants BoΔwadB and
BoΔwadC were affected not only in the LPS but also in
the topology of the outer membrane as detected with
anti-Omp MAbs. Little is known about how these changes
may affect the virulence of brucellae but it has been
shown that not all the B. melitensis R mutants are
equivalent in their surface properties and outer mem-
brane topology, and that they have different levels of
interaction with host cells, virulence and vaccination
power [12,18].
Recently, Conde-Álvarez et al. [6] proposed a new
strategy to develop vaccines against brucellosis based on
the concept that the surface molecules of Brucella effect-
ively evade a prompt detection by innate immunity [46],
and that surface changes such as those introduced by
mutations affecting the glucosamine branch of the core
would overcome hampered recognition thus producing a
protective Th1 response. This concept was based on a
comparison of a B. abortus wadC mutant and the
current vaccine B. abortus S19 in the mouse model [6].
Although we have not evaluated the immune response
in this work, our results add further weight to the value
of this strategy and show the possibility of obtaining vac-
cines against brucellosis caused by B. ovis that could be
used in areas free of B. melitensis. However, a potential
defect of these vaccines would be their interference in
the diagnosis of B. ovis, which is carried out using tests
that detect antibodies to both Omp and R-LPS [47]. These
problems, however, could be circumvented by the use of
antigenically-tagged brucellosis vaccines, a strategy re-
cently shown to be effective for the vaccine B. abortus S19
in the mouse model [48]. Research is in progress to evalu-
ate all these possibilities in sheep.
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